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Bromodomains (BRDs) are protein interaction
modules that specifically recognize ε-N-lysine acety-
lation motifs, a key event in the reading process of
epigenetic marks. The 61 BRDs in the human
genome cluster into eight families based on struc-
ture/sequence similarity. Here, we present 29 high-
resolution crystal structures, covering all BRD fami-
lies. Comprehensive crossfamily structural analysis
identifies conserved and family-specific structural
features that are necessary for specific acetylation-
dependent substrate recognition. Screening of more
than 30 representative BRDs against systematic
histone-peptide arrays identifies new BRD sub-
strates and reveals a strong influence of flanking
posttranslational modifications, such as acetylation
and phosphorylation, suggesting that BRDs recog-
nize combinations of marks rather than singly acety-
lated sequences. We further uncovered a structural
mechanism for the simultaneous binding and recog-
nition of diverse diacetyl-containing peptides by
BRD4. These data provide a foundation for struc-
ture-based drug design of specific inhibitors for this
emerging target family.
INTRODUCTION
ε-N-acetylation of lysine residues (Kac) is one of the most
frequently occurring posttranslational modifications (PTMs) in
proteins (Choudhary et al., 2009). Acetylation has a profound214 Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc.effect on the physiochemical properties of modified lysine resi-
dues neutralizing the positive charge of the ε-amino group
(Kouzarides, 2000). Lysine acetylation is abundant in large
macromolecular complexes that function in chromatin remodel-
ing, DNA damage, and cell-cycle control (Choudhary et al., 2009)
and particularly in histones. Cellular acetylation levels are
stringently controlled by two enzyme families: the histone acetyl-
transferases (HATs) and histone deacetylases (HDACs) (Shahba-
zian and Grunstein, 2007). Histone acetylation has been associ-
ated with transcriptional activation, but specific marks have also
been linked to DNA repair (Kouzarides, 2007).
Bromodomains (BRDs) are protein interaction modules that
exclusively recognize acetylation motifs. BRDs are evolutionarily
conserved and present in diverse nuclear proteins comprising
HATs (GCN5, PCAF), ATP-dependent chromatin-remodeling
complexes (BAZ1B), helicases (SMARCA), methyltransferases
(MLL, ASH1L), transcriptional coactivators (TRIM/TIF1, TAFs)
transcriptional mediators (TAF1), nuclear-scaffolding proteins
(PB1), and the BET family (Muller et al., 2011) (Figure 1A and
Table 1). Despite large sequence variations, all BRD modules
share a conserved fold that comprises a left-handed bundle of
four a helices (aZ, aA, aB, aC), linked by loop regions of variable
length (ZA and BC loops), which line the Kac binding site and
determine binding specificity. Cocrystal structures with peptides
have demonstrated that Kac is recognized by a central deep
hydrophobic cavity, where it is anchored by a hydrogen bond
to an asparagine residue present in most BRDs (Owen et al.,
2000).
Dysfunction of BRD proteins has been linked to development
of several diseases. For instance, recurrent t(15;19) chromo-
somal translocations that result in a fusion protein that
comprises both BRD4 or BRD3 and the NUT (nuclear protein in
testis) lead to an aggressive form of human squamous
carcinoma (French, 2010a; French et al., 2001). Deregulation of
transcription as a consequence of altered protein acetylation
patterns is a hallmark of cancer, a mechanism that is currently
targeted by HDAC inhibitors (Lane and Chabner, 2009). It is likely
that selective inhibitors capable of targeting BRDs will find broad
application in medicine and basic research as exemplified by the
recent development of highly specific and potent acetyl-lysine
competitive BET BRD inhibitors (Chung et al., 2011; Dawson
et al., 2011; Delmore et al., 2011; Filippakopoulos et al., 2010;
Mertz et al., 2011; Nicodeme et al., 2010).
To date, only a small number of lysine acetylation marks have
been identified to specifically interact with individual BRDs, and
the often weak affinities reported for BRD interactions with their
potential target sites have been determined by a variety of
different techniques making data comparison difficult (Muller
et al., 2011). Reported affinities range from nano- to millimolar
dissociation constant (KD) values raising the issue of which
affinity window is relevant for specific BRD-peptide interactions.
For instance, the BRDs of BRD2 have been shown to bind
histone 4 acetylated at lysine 12 (H4K12ac) (Kanno et al., 2004),
with KD values that range from 360 mM for the diacetylated
peptide H4K5acK12ac (Umehara et al., 2010) to 2.9 mM for the
monoacetylated H4K12ac peptide (Huang et al., 2007). Closely
spaced multiple Kac sites have also been shown to significantly
increase affinity of the histone H4 N terminus for BRDT by simul-
taneous binding to the same BRD (Morinie`re et al., 2009). Thus,
the field would greatly benefit from a more systematic analysis
of BRD structure and peptide binding properties in order to
better understand acetylation-mediated signaling as interpreted
through BRDs.
Here, we present a comprehensive structural characterization
of the human BRD family together with identified Kac-specific
interaction sites of these essential protein recognition modules
with their target sites in histones. Using available sequence data-
bases, we identified 61 BRDs in the human proteome that are
present in 46 diverse proteins. High-throughput cloning led to
the establishment of 171 expression systems that yielded func-
tional recombinant proteins. Using these reagents, we crystal-
lized and determined the structures of 29 BRDs, including 25
structures that had not been previously published. We per-
formed a SPOT blot analysis that covered all possible Kac sites
of human histones (Nady et al., 2008) for 43 members of the
BRD family. We identified 485 linear Kac-dependent BRD-
binding motifs, and determined accurate binding affinities in
solution for 81 known cellular histone marks by isothermal titra-
tion calorimetry (ITC). Furthermore, we found that BRD peptide
recognition is dependent on patterns of multiple modifications
rather than on a single acetylation site. This study provides
a comprehensive structural comparison of this protein family
interpreted in the context of a large array of histone interaction
data, establishing a powerful resource for future functional
studies of this family of epigenetic reader domains.
RESULTS
The Human BRD Family
Analysis of sequence databases (NCBI, UniProt, PFAM) identi-
fied 46 diverse human proteins that contain a total of 61 diverseBRDs. BRD-containing proteins are large multidomain proteins
associated with chromatin remodeling, transcriptional control,
methyl or acetyltransferase activity, or helicases (Figure 1A and
Table 1). The domain organization in BRD-containing proteins
is evolutionarily highly conserved, and the BRD motif is often
flanked by other epigenetic reader domains. Most frequently
observed combinations include the presence of plant homeodo-
mains (PHDs) N terminal to the BRD, multiple BRDs, as well as
various other domains that generally mediate protein interac-
tions such as bromo-adjacent homology (BAH) domains (Good-
win and Nicolas, 2001).
Phylogenetic analysis of theBRD family outside the two central
core helices was complicated by the low-sequence homology
and nonconserved insertions in BRD loop regions. We therefore
used three-dimensional structure-based alignments including
available NMRmodels together with secondary structure predic-
tion (Jones, 1999) and manual curation of the aligned sequences
to establish an alignment of all human BRDs (Figure S1). The
derived phylogramclustered into eightmajor BRD families desig-
nated by Roman numerals (I–VIII) (Figure 1B). Key references for
all BRD-containing proteins are included in Table 1.
Multiple protein interaction modules can be tightly linked to
form a single stable interaction domain, or they can be con-
nected by flexible linker sequences allowing conformational
adaptation to diverse sequences motifs. An example of a tightly
linked dual-domain reader is the PHD-BRD of TRIM24, in which
both domains interact through a large interface that orients both
peptide binding cavities to the same side of the protein (Tsai
et al., 2010). In contrast, the two BRDs in TAF1 are free to orient
independently as shown by the different domain orientations
in the dual-domain structure determined here and a previously
published model (Jacobson et al., 2000) (Figure 1C). The fre-
quent combination of multiple interaction modules in the same
protein suggests that the epigenetic reading process involves
concomitant recognition of several PTMs.
Structural Analysis
In order to establish a platform of recombinant BRDs for func-
tional and structural studies, we subcloned all human BRDs
into bacterial expression systems in frame with a cleavable
N- (or C-) terminal His6 tag. A total of 1,031 constructs resulted
in the identification of 171 expression systems covering 44
BRDs that yielded stable and soluble proteins. Details of the
cloned constructs are summarized in Table S1, and descriptions
of one representative expression system per BRD are summa-
rized in Table S2. The expressed proteins provide an excellent
coverage of representative BRDs of all eight families.
A total of 133 recombinant BRD constructs covering 44 unique
BRDs were expressed at levels sufficient for structural studies,
resulting in the determination of a total of 33 crystal structures
of apo-BRDs (Table S3), or BRDs in complex with acetylated
peptides (Table S4). Together with previously published struc-
tural information, each BRD family is represented by at least
one structural model, and families I, II, and VIII are either
completely or nearly completely covered (Figure 1B). All struc-
tures presented here were refined at high resolution. A summary
of the crystallization conditions, data collection, and refinement
statistics is compiled in Table S5.Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc. 215
AB C
D
Figure 1. Domain Organization, Phylogenetic Tree, and Overall Fold of BRDs
(A) Domain organization of representative proteins that contain BRDs. The name and the length of the selected proteins are shown on the bar chart in the left
panel. The positions of the different domains are highlighted as shown by the legend on the right.
(B) Phylogenetic tree of the human BRD family. The different families are named by Roman numbers (I–VIII). Structures determined in this study, by NMR, or by
other groups are indicated by blue, red, and green dots, respectively.
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Despite the low degree of overall sequence homology, all
BRDs shared a conserved overall fold comprising four a helices
(aZ, aA, aB, aC) linked by highly variable loop regions (ZA and BC
loops) that form the docking site for interacting recognition
motifs (Figures 1D and S2A). The C and N termini are highly
diverse and may comprise additional helices that extend
the canonical BRD fold (e.g., the sixth BRD of PB1 has an addi-
tional C-terminal helix) or largely extended kinked helices that
are present as C- or N-terminal extensions (for instance in
TAF1L or ATAD2). The four helices form a deep cavity that is
extended by the two loop regions (ZA and BC loops), creating
a largely hydrophobic Kac binding pocket. The most notable
structural difference within the BRD core fold is a hairpin inser-
tion located between helix aZ and the ZA loop that is present in
all family VIII members. The proximity to the Kac binding site
suggests that this insert may play a role in recruitment of acety-
lated binding partners. Loop insertions are frequently found
within the ZA loop, resulting in substantial differences in the
rim region of the binding pocket. Hydrophobic residues in the
ZA loop may contribute to protein instability and the low crystal-
lization success rate observed in our work for BRDs of families VI
and V. Indeed, in the recently published structure of the MLL
tandem PHD-BRD module, a flexible insertion found in the
MLL ZA loop was deleted in order to generate a more stable
construct (Wang et al., 2010).
In stark contrast to the conserved fold of BRDs (Figure S3A),
their surface properties are highly diverse. The electrostatic
potential of the surface area around the Kac binding site ranges
from highly positively to strongly negatively charged, suggesting
that BRDs recognize largely different sequences (Figure 2).
Based on their surface properties, interactions with highly basic
histones are not likely for BRDs with highly positive surfaces, as
observed for instance for the third BRD of PB1.
Structural superimposition of 33 BRD crystal structures
and 4 NMR models revealed conserved motifs throughout the
folded protein domain. To refer to specific sites, we chose
the first BRD of BRD4 as a reference sequence for numbering
of residues (Figure S2A). The N-terminal helix aZ is highly
diverse, but it contains three conserved hydrophobic residues
oriented toward the core of the helical bundle. This conserved
motif follows the generic sequence f1x1x2(x3)f2x3x4x5(x6)f3,
where fi are hydrophobic residues, and xj represent any amino
acid. The insertions at x3 are present in the N-terminal domain
of BET family members. Insertions x6 are present in the
C-terminal BRDs of TAF1 and TAF1L and possibly PRKCBP1
(Figures S2A and S2B). Helix aZ is flanked by a diverse sequence
region and a b hairpin insert present in all family VIII BRDs
(Figures S1 and S3B). These diverse loop inserts are typically
followed by a short helical segment in the ZA loop. The C
terminus of the helical segment is stabilized by a highly
conserved phenylalanine (F83 in BRD4(1)) that is deeply buried
by hydrophobic residues present in helix aC, bridging both(C) Domain flexibility as seen in the tandem BRD modules of TAF1 di-domain stru
the ability of BRDs to adopt different relative orientations that may influence the
(D) Overall structure of the BRD4(1) BRD. N and C termini and secondary structu
See also Figure S1.sides of the helical bundle (Figure S2C). The ZA loop harbors
also three conserved proline residues in addition to hydro-
phobic residues such as the conserved V87/Y97 pair that
closely pack to hydrophobic residues present in aC stabilizing
the loop conformation. A conserved tyrosine (Y97) defines the
N terminus of the ZA loop helix present in all BRDs except
TRIM28 and the sixth BRD of PB1, which have unusually short
ZA loops that have lost this structural element (Figures 3A
and S2C).
Helix aA is preceded by a Pf1D motif (f1 is a hydrophobic
residue). The conserved aspartate caps the helix aA forming
a hydrogen bond with a backbone amide. Also for this helix,
the main sites of conservation are hydrophobic residues that
contribute to the stability of the core of the structure (Figure 3B).
The loop region AB contains a highly conserved tyrosine
(Y119) that hydrogen bonds to a conserved aspartate (D128)
located in helix aB, presumably stabilizing the loop-helix fold.
The long helix aB shows a conserved pattern of the sequence
fxxDfxxffxNfxxY/F (Figure 3C). A conserved asparagine
(N135) hydrogen bonds with the ZA loop backbone linking to
this aB loop region that is additionally stabilized by a small hydro-
phobic core formed around the conserved aromatic residue
(Y139) preceding the Kac docking residue (N140). An asparagine
residue that anchors Kac by formation of a critical hydrogen bond
initiates the BC loop. Structural comparison suggested that this
asparagine can be replaced by other hydrogen bond donors,
such as threonine or tyrosine side chains. In MLL, however, an
aspartate occupies this position suggesting that this domain
either does not bind acetylated lysine residues or has a signifi-
cantly different mechanism to recognize its target sequence.
Similar to helix aZ, the C-terminal helix aC exhibits little sequence
conservation apart from a number of hydrophobic core residues
(Figure 3D). In summary, we have identified several highly
conserved sequence motifs in BRDs that serve to stabilize the
structural fold and conformation of loop regions flanking the
Kac binding pocket. An overview of the sequence conservation
is shown in Figure S2D.
Interactions of BRDs with Histone Acetylation Sites
Histone tails are hot spots of PTMs that play key roles in regula-
tion of transcription and all aspects of chromatin biology.
However, to date, no systematic study has addressed binding
specificity of reader domains. Here, we used SPOT peptide
arrays that cover all possible Kac sites of the human histones
(H1.4, H2A, H2B, H3, and H4) in order to identify interaction sites
for 33 representative BRDs. To distinguish between Kac-depen-
dent and independent binding, we also included all correspond-
ing unmodified peptides. In general, affinities of Kac for BRDs are
low, suggesting that additional interaction domains may be
required for higher affinity target-specific binding, in vivo. In
some cases we observed Kac-independent interaction of BRDs
with nonacetylated control peptides. To date, it is not clearcture (orange PDB: 1EQF) and a new structure (green PDB: 3UV5), highlighting
recognition of their target sequences.
re elements are labeled.
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Table 1. Human Bromodomain Family
Protein Name Alias Protein Function
Subcellular
Localizationa UniProt ID Reference
ASH1L ash1 (absent, small,
or homeotic)-like
ASH1, KMT2H Methyltransferase N, C Q9NR48 (Gregory et al., 2007)
ATAD2 Two AAA domain
containing protein
ANCCA Transcriptional
regulator
N Q6PL18 (Ciro´ et al., 2009)
BAZ1A Bromodomain adjacent
to zinc finger domain, 1A
ACF1, WALp1,
WCRF180
Chromatin
remodeling factor
N Q9NRL2 (Racki et al., 2009)
BAZ1B Bromodomain adjacent
to zinc finger domain, 1B
WSTF, WBSCR9 Chromatin
remodeling factor,
transcriptional
regulator
N Q9UIG0 (Cavella´n et al., 2006)
BAZ2A Bromodomain adjacent
to zinc finger domain, 2A
TIP5, WALp3 Transcriptional
repressor
N, C Q9UIF9 (Zhou et al., 2009)
BAZ2B Bromodomain adjacent
to zinc finger domain, 2B
WALp4 Unknown N, C Q9UIF8 (Jones et al., 2000)
BRD1 Bromodomain-containing
protein 1
BRL, BRPF2 Transcriptional
regulator, scaffold
protein
N, C O95696 (Ullah et al., 2008)
BRD2 Bromodomain-containing
protein 2
FSH, RING3 Transcriptional
regulator
N P25440 (LeRoy et al., 2008)
BRD3 Bromodomain-containing
protein 3
ORFX, RING3L Transcriptional
regulator
N Q15059 (LeRoy et al., 2008)
BRD4 Bromodomain-containing
protein 4
CAP, MCAP,
HUNK1
Transcriptional
regulator
N O60885 (Yang et al., 2008)
BRD7 Bromodomain-containing
protein 7
BP75, NAG4,
CELTIX1
Transcriptional
regulator
N Q9NPI1 (Kaeser et al., 2008)
BRD8B Bromodomain-containing
protein 8 B
SMAP, SMAP2 Transcriptional
regulator
N Q9H0E9-2 (Cai et al., 2003)
BRD9 Bromodomain-containing
protein 9
Unknown N, C Q9H8M2 NA
BRDT Bromodomain-containing
protein, testis specific
BRD6 Chromatin
remodeling factor
N Q58F21 (Morinie`re et al., 2009)
BRPF1 Bromodomain- and PHD
finger-containing protein 1A
BR140, Peregrin Transcriptional
activator
N, C P55201-1 (Laue et al., 2008)
BRPF3 Bromodomain- and PHD
finger-containing protein, 3
Unknown N Q9ULD4 NA
BRWD3 Bromodomain-containing
protein disrupted in leukemia
BRODL JAK-STAT
signaling
N, C Q6RI45 (Mu¨ller et al., 2005)
CECR2 Cat eye syndrome
chromosome region
Chromatin
remodeling factor
N Q9BXF3 (Fairbridge et al., 2010)
CREBBP CREB-binding protein CBP, KAT3A Histone acetyl
transferase
N Q92793 (Kalkhoven, 2004)
EP300 E1A-binding protein p300 p300, KAT3B Histone acetyl
transferase
N Q09472 (Kalkhoven, 2004)
FALZ Fetal Alzheimer antigen BPTF, FAC1 Transcription factor N Q12830 (Li et al., 2006)
GCN5L2 General control of amino
acid synthesis 5-like 2
KAT2A, GCN5 Histone acetyl
transferase
N Q92830 (Yang et al., 1996)
KIAA1240 KIAA1240 protein ATAD2B Unknown N Q9ULI0 NA
LOC93349 SP140-like SP140L Unknown U Q13342 NA
MLL Myeloid/lymphoid or mixed
lineage leukemia (trithorax
homolog, Drosophila)
HRX, TRX1,
CXXC7, ALL-1
Histone methyl
transferase
N Q03164 (Dou et al., 2005)
PB1 Polybromo 1 PBRM1, BAF180 Chromatin
remodeling factor
N, C Q86U86 (Xue et al., 2000)
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Table 1. Continued
Protein Name Alias Protein Function
Subcellular
Localizationa UniProt ID Reference
PCAF P300/CBP-associated factor KAT2B Histone acetyl
transferase
N Q92831 (Dhalluin et al., 1999)
PHIP Pleckstrin homology
domain-interacting protein
WDR11, ndrp Insulin signaling N Q8WWQ0 (Podcheko et al., 2007)
PRKCBP1 Protein kinase C-binding
protein 1
ZMYND8, RACK7 Transcriptional
regulator
N Q9ULU4 (Fossey et al., 2000)
SMARCA2 SWI/SNF-related matrix-
associated actin-dependent
regulator of chromatin a2
BRM, SNF2L2 Chromatin
remodeling factor,
Splicing regulator
N P51531 (Harikrishnan et al., 2005)
SMARCA4 SWI/SNF-related
matrix-associated
actin-dependent regulator
of chromatin a4
BRG1, SNF2L4,
SNF2LB
Chromatin
remodeling factor
N P51532 (Rada-Iglesias et al., 2011)
SP100 Nuclear antigen Sp100 Transcriptional
regulator
N, C P23497 (Yordy et al., 2005)
SP110 Nuclear antigen Sp110 A,
nuclear antigen Sp110 C
IPR1 Transcriptional
regulator
N Q9HB58 (Bloch et al., 2000)
SP140 SP140 nuclear body protein LYSP100 Transcriptional
regulator
N, C Q13342 (Zong et al., 2000)
TAF1 TAF1 RNA polymerase II,
TATA box-binding protein
(TBP)-associated factor
TAFII250 Transcription
initiation
N P21675 (Wassarman and Sauer,
2001)
TAF1L TAF1-like RNA polymerase II,
TATA box-binding protein
(TBP)-associated factor
TAF(II)210 Transcription
initiation
N Q8IZX4 (Wang and Page, 2002)
TIF1a Transcriptional intermediary
factor 1
TRIM24, PTC6,
RNF82,
Transcriptional
regulator
N, C O15164 (Tsai et al., 2010)
TRIM28 Tripartite motif-containing 28 KAP1, RNF96,
TIF1b
Transcriptional
regulator
N Q13263 (Rowe et al., 2010)
TRIM33 Tripartite motif-containing 33 A PTC7, RFG7,
TIF1g
Control of
transcription
elongation
N Q9UPN9 (Bai et al., 2010)
TRIM66 Tripartite motif-containing 66 TIF1d Transcriptional
repressor
N O15016 (Khetchoumian et al., 2004)
WDR9 WD repeat domain 9 BRWD1 Chromatin
remodeling factor
N Q9NSI6 (Huang et al., 2003)
ZMYND11 Zinc finger, MYND domain
containing 11
BS69, BRAM1 Transcriptional
repressor
N Q15326 (Masselink and Bernards,
2000)
aNuclear (N) or cytoplasmic (C).whether BRDs participate in Kac-independent protein interac-
tions as it has been described for PHDs that recognize a broad
variety of differently methylated, acetylated, and nonmodified
peptides (Lan et al., 2007; Org et al., 2008; Tsai et al., 2010).
We identified 485 interactions of BRDs to histone peptides
that depend on the presence of a single Kac site (Figures 4 and
S4; Table S6). The nuclear body protein SP140 as well as the
related protein LOC93349 and PCAF showed nonspecific
binding to most peptides. In contrast, the second, fourth, fifth,
and sixth BRD of PB1, MLL, and TRIM28 interacted with only
a few histone Kac peptides. Also, a number of promiscuous
sequences were identified, such as the H2AK36 and H2BK85-
containing peptides that interacted with most BRDs. To validatethe detected interactions and to obtain accurate binding
constants in solution, we synthesized 53 singly acetylated
peptides and determined binding constants by ITC (Table S7).
We included also 14 peptides that did not bind to BRDs in the
SPOT array. As expected these peptides did not show measur-
able interactions by ITC, suggesting that false negatives are not
a major concern in the SPOT array study. Also in agreement with
the array study, binding of 20 identified interacting peptides was
confirmed by ITC experiments showing KD values between 3
and 300 mM. However, 16 peptides that were selected based
on published recognition sites did not give rise to detectable
interactions in the SPOT array and still exhibited KD values
between 10 and 730 mM by ITC. The detection limit of SPOTCell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc. 219
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I
III
IVV
VIIVI
VIII
II
BRD1
3RCW
WDR9(2)
3Q2E
BRD9
3HME
BRD7
2I7K
BRPF1B
2D9E
ASH1L
3MQM
ATAD2
3DAI
BAZ2B
3G0L
MLL
3LQH
TRIM28
2RO1
BRD3(1)
2NXB
BRD3(2)
2OO1
BRD4(1)
2OSS
BRD4(2)
2OUO
BRDT(1)
2RFJ
CECR2
3NXB
CREBBP
3DWY
EP300
3I3J
FALZ
3UV2
GCN5L2
3D7C
KIAA1240
3LXJ
PB1(4)
3TLP
PB1(1)
3IU5
PB1(2)
3HMF
PB1(3)
3K2J
PB1(5)
3G0J
SMARCA2B
2DAT
PB1(6)
3IU6
PCAF
3GG5
PHIP(2)
3MB3
TAF1(2)
3UV4
TAF1(1)
3UV5
TAF1L(2)
3HMH
BRD2(1)
1X0J
BRD2(2)
2DVV
TIF1α
2YYN
SMARCA4
3UVD
Figure 2. Electrostatic Surface Potential of Human BRDs
The domains are grouped into the eight BRD families (shown in roman numerals). Electrostatic surface potentials are shown between10kT/e (red) and +10kT/e
(blue). The BRD names and structures (PDB accession code in black for crystal structures and red for NMRmodels) are shown in the figure. All domains are shown
in identical orientation with their acetyl-lysine binding site facing the reader and highlighted with a dashed circle on the top-left structure (PCAF). See also
Figure S3.arrays is about 500 mM, but the data suggest that SPOT arrays
do not detect all possible interacting motifs. Steric constraints
of the immobilized peptides and potentially the lack of sufficient
N- and C-terminal flanking regions are themost likely reasons for
the failure to detect BRD recognition motifs in SPOT arrays. In
addition, 35 (12%) of acetyl-lysine containing peptides were
not recognized by acetyl-lysine specific antibodies. However,
most of these peptides contained proline residues in close prox-
imity of the Kac site, a likely reason for the failure of the antibody220 Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc.to recognize these sites. Other peptides showed crossreactivity
with the His6 antibody and have been removed from the analysis.
The false negative rate was particularly high for BET family
members. Recently, it was demonstrated that murine BRDT
preferentially recognized diacetylated motifs, whereas most
monoacetylated peptides tested did not bind tightly to mBRDT
BRDs (Morinie`re et al., 2009). This observation prompted us to
design a systematic histone H3 array in which we explored
combinations of acetylated and trimethylated (Kme3) lysines as
A B
C D
Figure 3. Conserved Residues and Sequence Logos
Conserved residues are shown as sequence logos (lower panel in each figure), and their location is shown in the ribbon diagram above. Secondary structure
elements and residue labels are colored in all figuresas follows:aZ, blue;aA, pink;aB, green;aC, brown;ZA loop,magenta.Motifs and location of residues are shown
for (A) ZA loop, (B) helix aA and AB loop, (C) AB loop and helix aB, and (D) helix C. The conserved Kac docking residue (N140) is shown in cyan. See also Figure S2.well as phospho-serine/phospho-threonine (pS/pT) modifica-
tions around each acetylated lysine (Figures 5 and S5).
Interactions previously reported for singly acetylated lysine
sites were largely confirmed. Interestingly, most of the 43
BRDs tested were highly sensitive to modifications flanking
the Kac mark. For instance, BRD4(2) did not interact with H3
peptides singly acetylated on K4. In contrast, this domain
showed strong interaction with diacetylated H3 (H3K4acK9ac)
but not with the same peptide acetylated at K4 but trimethy-
lated at K9 (H3K4acK9me3). The strongest interaction was
observed using diacetylated H3K4acK9ac in combination with
phosphorylation at T3. Similarly, the BRD of FALZ showed no
interaction with non- or singly acetylated K4 but interactedstrongly with H3 pT3K4acK9ac. Also, WDR9(2) and EP300
exclusively interacted with the triply modified H3 pT3K4acK9ac
peptide. The WDR9(2) interaction with H3K14ac showed strong
dependence on S10 and T11 phosphorylation as well as acet-
ylation at K18. Indeed, ITC experiments showed that the
binding affinity of many BRDs was significantly increased for
multiply modified peptides (Tables S7 and S8). For example,
the KD of CREBBP decreased from 733 mM for H3K14ac to
131 mM for H3pS10K14acK18ac suggesting that many BRDs
recognize a pattern of modifications rather than a single Kac
mark.
To obtain better insight into BRD recognition of multiply
acetylated histone tails, we designed a systematic m-SPOTCell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc. 221
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array of peptide 11-mer that harbored multiple Kac sites of the
N-terminal tails of histones H3 and H4 (Figure 6A). Screening
against BRDs of the BET family showed that BRD4(2) inter-
acted with most combinations of two and three acetylated
lysines, whereas BRD4(1) seemed to specifically recognize
multiple marks found on the H4 tail. A tetra-acetylated H4
peptide that contained the acetylation sites K5, K8, K12, and
K16 bound with single-digit micromolar KD values to the first
BRDs of BRD2 and BRD4, increasing affinity at least 20-fold
when compared to single marks. The second BET BRDs
bound to tetra-acetyl H4 peptides with about 10-fold weaker
affinities, suggesting that the first BRD in BET proteins recog-
nizes the H4 tail (Figure 6B). Recently, it was demonstrated
that BRDT requires two Kac residues for high-affinity binding
(Morinie`re et al., 2009). Our peptide binding data suggest
that the BET family and several other BRDs may also recog-
nize multiply acetylated peptides. However, our binding data
cannot discriminate between simultaneous recognition of two
Kac as opposed to increased avidity for a multiply modified
peptide. In order to determine whether the diverse sequence
and spacing of histone Kac residues can be accommodated
by a single BRD, we systematically determined cocrystal struc-
tures of BRD4(1) with the diacetylated peptides H4K5acK8ac,
H4K12acK16ac, and H4K16acK20ac. In all cases the two acety-
lated lysines bound simultaneously and with identical confor-
mations to the BRD4(1) Kac binding site (Figure 6C).
The N-terminal Kac always formed the anchoring hydrogen
bond with the conserved asparagine (N140). In the N-terminal
region of H4, flexible glycine residues allow variable peptide
conformations with two (H41–11K5acK8ac; Figure S6A) or three
(H411–21K12acK16ac; Figure S6B) linking residues, whereas
the large side chains in H415–25K16acK20ac (Figure S6C) fit
perfectly into surface grooves created by the ZA and BC
loops. These structures explain the similar affinities observed
for the various combinations of di- and triacetylated H4
peptides. They also suggest that the greater apparent affinity
of BRD4(1) and BRD2(1) for tetra-acetylated H4 peptides is
an avidity effect. However, not all diacetylated H4 sequences
are compatible with this bidentate recognition process. The
cocrystal structure of H47–17K8acK12ac with BRD4(1) revealed
a canonical monoacetylated recognition mode (Figure S6D),
suggesting that the H49–11 linker sequence is not suitable for
a simultaneous recognition of the two Kac by a single BRD.
Consistent with this notion, ITC experiments revealed a binding
stoichiometry (N) of 0.5, indicating binding of two BRDs to the
H4K8acK12ac peptide, whereas only a single binding event with
significantly increased affinity was observed for the H4K5ac
K8ac peptide (Table S8). A representative set of ITC data is
shown in Figure 6D.
Wewere interested in the sequence requirements of the diace-
tyl-lysine BET recognition and designed a systematic peptide
array in which we modulated the spacer sequence and residueFigure 4. Detected Interactions of BRDs with Histones in SPOT Arrays
A total of 33 BRDs were screened against an array of singly acetylated peptides t
H3, and H4 (left panel). Non-Kac specific interaction (corresponding nonacetylated
indicated in the figure. See also Figure S4.properties of residues located between the two Kac binding sites
(Figures 7A andS7). For the first BRDs of theBET family, a spacer
of two glycine residues was optimal. However, BRD2(1) also
tolerated longer linker sequences. For two-residue linkers, bulky
amino acids in the first linker position were not tolerated,
but changes of residue properties in the second linker position
did not strongly influence binding. Intriguingly, the wild-type
sequence ‘‘GG’’ of the H4 K5/K8 linker region seems highly opti-
mized for interaction of the first BRD of BET family members.
Binding of di-Kac marks separated by three residue spacers as
found in sequences linking the H4 K8/K16 and K16/K20 required
a glycine or a hydrophobic residue in the first linker position
for optimal binding to the first BET BRDs. Acidic residues in
any linker position led to loss of interaction with H4 histone tail
peptides. In contrast, the second BRDs of BET BRDs bound
either weakly (BRD2), not at all (BRD3), or promiscuously
(BRD4) to histone sequences and their variants present in this
array. ITC data collected on the first BRD of BRD4 showed a
30-fold increase in affinity between the singly acetylated peptide
H4K5ac to the most optimal wild-type peptide H4K5acK8ac.
In contrast, diacetylation had only a modest effect on binding
affinities of the second BRD of BRD4. As reported for interac-
tions with single acetylation sites in the case of the BRDs
of BRD2 (Umehara et al., 2010), alanine mutants of the
conserved asparagine (N140 and N443 in the first and second
BRDs in BRD4) did also abolish binding of diacetylated peptides
in both SPOT assays as well as in ITC (Figures 7B and 7C;
Table S9).
In order to address the question of whether full-length BRD4
also interacts with the identified Kac sites in the context of intact
nucleosomes, we performed pull-down assays on nucleosomal
preparations using Flag-tagged BRD4 and antibodies that
specifically recognize Kac sites. In agreement with our peptide
array studies, we identified histone interaction of BRD4 with
the H4 sites K5ac, K8ac, K12ac, K16ac, and H3 K14ac (Figure 7D).
Unfortunately, no antibodies are currently available that specifi-
cally recognize diacetylated marks in histones H3 and H4.
We therefore analyzed Kac-enriched tryptic digests prepared
from pull-downs of salt-extracted histone using C-terminally
biotinylated BRD4(1) and BRD4(2) by mass spectroscopy (Fig-
ure 7E). We were able to detect numerous polyacetylated
histone peptides associated with BRD4 BRDs; incubation with
the active BRD4 inhibitor (+)-JQ1 (Filippakopoulos et al., 2010),
but not its inactive stereoisomer ()-JQ1, abrogated interaction
with acetylated histones, indicating that the purifications were
specific. Importantly, we observed that the first BRD, BRD4(1),
interacted mostly with polyacetylated histone H4 peptides
and that the majority of peptides identified contained at least
two Kac sites. These results are in good agreement with the
strong increase in binding affinity and the preference for
BRD4(1) for histone diacetyl marks observed in our in vitro
binding studies.hat cover all possible acetylation sites in histones H1.4 (right panel), H2A, H2B,
) peptides are shaded in gray. Spots are shaded by different spot intensities as
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Figure 5. Influence of Neighboring PTMs on BRD Interaction with Histone H3
Shown are interactions detected in SPOT arrays shaded by spot intensity as indicated in the legend at the upper-left corner of the figure. The influence of lysine
trimethylation (Kme3), acetylation, and phosphorylation (pT, pS) has been studied on binding to a central acetylated lysine epitope. The combination of the different
modifications is indicated in the right panel. Nonmodified peptides have been included as controls to identify interactions independent of lysine acetylation. See
also Figure S5.
224 Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc.
0 20 40 60 80
-8
-6
-4
-2
0
 Time (min)
Δ
P
 (
μ
c
a
l/
s
e
c
)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
Molar Ratio
-25
-20
-15
-10
-5
0
 k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
H4     K5acK8ac
1-11
H4     Kac4
1-20
H4K5acK8ac
H4K12acK16ac
H4K16acK20ac
αZZA-loop
BC-loop
αB αC
7
-1
7
8
12
3
-1
3
5
8
12
3
-1
3
8
12
3
-1
3
5
8
1
-1
0
5
8
1
5
-2
5
16
20
1
1
-2
1
1
-1
0
12
16
20
1
1
-2
1
16
20
1
1
-2
1
12
16
7
-1
7
8
12
16
7
-1
7
12
16
2
2
-3
2
23
27
3
1
-4
1
36
37
1
8
-2
8
18
23
27
1
8
-2
8
23
27
1
8
-2
8
18
23
1
3
-2
3
1
8
-2
8
2
2
-3
2
9
-1
9
4
-1
4
1
-9
14
18
23
1
3
-2
3
18
23
1
3
-2
3
14
18
9
-1
9
9
14
18
9
-1
9
14
18
9
-1
9
9
14
4
-1
4
4
9
14
4
-1
4
9
14
4
-1
4
4
9
1
-9
4
9 5
1
4
3
11
9
14
11
28
23
28
27
BRD2(1)
BRD2(2)
BRD3(1)
BRD3(2)
BRD4(1)
BRD4(2)
BRDT(1)
skraM4enotsiHskraM3enotsiH
No SPOT
Very Weak
Weak
Strong
Very Strong
H
is
to
n
e
P
e
p
ti
d
e
S
e
q
u
e
n
c
e
Controls (Q7-13)
Histone H4 Kac/pS (Q6)
Histone H3 Kac/pS/pT (Q1-5)
Histone H4 poly-Kac (O16-O20, P1-P6)
Histone H3 poly-Kac (O1-O15)
Kac pT/pS|
8
|
5
|
12
|
16
|
20
SGRGKGGKGLGKGGAKRHRKVLRDNI...H4
14
|
18
|
23
|
27
|
36
|
37
|
4
|
9
|
ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYR ...H3
N-term
O
P
Q
O
P
Q1 2 3 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 204
1 2 3 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 204
BRD4(2)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
BRD4(1)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
H2a
H2b
H3
H4
H1,4
Poly
Kac
A
B
DC
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(C) Structural overlay of diacetylated peptides to the Kac binding site of BRD4(1). The bindingmode is retained, although the linker betweenmarks and the flanking
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(D) Two representative ITC traces of polyacetylated histone H4 peptide binding to BRD4(1). Peptide sequences are shown in the inset.
See also Figure S6.DISCUSSION
Recent developments in biotechnology and structural biology
have facilitated rapid generation of structural data enabling
determination of high-resolution structures of most members
of certain protein families within a short time frame (Barr et al.,2009). The study presented here represents a comprehensive
structural description of the entire human BRD family with at
least one representative structural model for each branch in
the BRD phylogenetic tree. Structural coverage of families I, II,
and VIII is complete or nearly complete. These crystal structures
enabled a detailed sequence comparison of this highly diverseCell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc. 225
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(A) Effect of poly-Gly and linker sequence on binding of doubly acetylated peptides to BET BRDs profiled by SPOT assays. Interactions are weakened or
abolished when the docking asparagine is mutated to an Ala (N140A for the first and N433A for the second BRDs of BRD4).
(B) Effect of poly-Gly linker on the binding of H4K5acK8ac to BRD4(1) evaluated by ITC, demonstrating that the natural recognition sequence has the optimal
sequence for binding. Peptide sequences are given in the inset.
(C) The second BRD of BRD4 is more promiscuous as demonstrated by ITC, exhibiting weaker binding for all tested peptides.
(D) Immunoprecipitation of Flag-tagged BRD4 from transfected cell nucleosome fraction and western blotting using anti-acetylated histone antibodies. Input
represents 1% of total input. IgG was used for control immunoprecipitations.
(E) Individual BRD4 BRDs purify histones with distinct acetylation status from histone fractions. Acetylated histone peptides associated with biotinylated BRD4(1)
or BRD4(2) were identified by LC-MS/MS, and the relative peak intensity of individual peptides was expressed as a ratio of peak area of the specific peptide to the
sum of all peak areas for acetylated histone peptides in each sample.
See also Figure S7.
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domain family. Importantly, although the protein family database
Pfam (Finn et al., 2010) extended the BRD fold from the initially
predicted central helices aA and aB (Haynes et al., 1992) to
a 110 residue motif (Jeanmougin et al., 1997), sequence-based
tools still fail to predict correct domain boundaries for BRDs
that contain long ZA and BC loop insertions. The excellent struc-
tural coverage of the BRD family enabled the identification of
BRD signature motifs and family-specific secondary structure
elements, such as the ZA loop helix aAZ and the subfamily VIII-
specific b hairpin insert.
Probing BRD Histone Recognition by Peptide Arrays
Peptide arrays offer a rapid technology for screening protein-
peptide interactions. The technology was developed more than
a decade ago (Reineke et al., 2001) and has recently been
applied to study epigenetic methyl-lysine reader domain interac-
tions with histone tails (Nady et al., 2008, 2011). Recent progress
in array technology allows peptide densities of up to 40,000
spots per square centimeter of solid support, enabling in prin-
ciple genome-wide analysis of reader domains with peptidic
recognition motifs (Beyer et al., 2009). To date, more than 100
histone PTMs that function as recruitment platforms for chro-
matin proteins have been described (Kouzarides, 2007). We
chose, therefore, a systematic peptide array that covered all
possible histone acetylation sites to characterize a representa-
tive set of BRD reader domains. However, many BRDs may
interact with acetylation sites present in nonhistone proteins. In
fact, we did not observe interaction with histone peptides for
a number of BRDs.
Recognition sites for only a few BRDs have been previously
characterized, and reported substrate affinities range from the
low micromolar to the millimolar KD range. Specific recognition
sites in histones identified by our SPOT arrays that contained
only a single Kac site per peptide had binding affinities between
3 and 350 mM, which fall into the affinity range that has been
reported for other BRD-Kac interactions (Shen et al., 2007;
Zeng et al., 2008). However, comparison of binding constants
determined in solution by ITC with SPOT intensity did not always
correlate, suggesting that peptides linked to cellulose supports
used in this study did not allow quantification of binding affinities.
However, a recent study found good correlation with SPOT
intensities and substrate KM values for deacetylases indicating
improved correlation for proteins with enzymatic activity (Smith
et al., 2011).
Many BRDs Recognize Patterns of PTMs
The weak contribution of the Kac mark to the binding affinity of
BRDs to their target sites makes BRD interactions particularly
sensitive to changes in the environment of the Kac site. The
high density of PTMs in histones and other signaling molecules
results in a large number of potential combinations of marks
that regulate chromatin-templated recognition processes. In
this study we selected a limited but systematic set of combina-
tions that may be present in histone H3 and comprehensively
profiled this array against the human BRD family. The observed
strong influence of neighboring PTMs, such as phosphoryla-
tion, on recognition of their target sites by BRDs suggests tight
coupling of phosphorylation signaling with epigenetic mecha-nisms of regulation. Many examples of this coupling have
been reported for chromatin-modifying enzymes. For instance,
H3S10 phosphorylation has been shown to be functionally
linked to GCN5-mediated acetylation at H3K14 (Lo et al.,
2000, 2001), and crosstalk of the three marks, H3K9ac,
H3pS10, and H4K16ac, regulates transcriptional elongation of
certain genes by providing a nucleosome platform that recruits
BRD4/P-TEFb (Zippo et al., 2009). Also, H3pS10 is a prerequi-
site for H3K4 trimethylation (Li et al., 2011), which in turn has
been shown to prevent phosphorylation at H3T3 by haspin (Es-
waran et al., 2009). These data strongly suggest that combina-
torial motifs rather than single PTMs determine the cellular
outcome of processes regulated by epigenetic reader
domains. This hypothesis would also explain the large amount
of contradictory results in studies where single marks have
been assigned specific function such as transcriptional activa-
tion or silencing. Thus, the reading process of the ‘‘histone
code’’ is a sophisticated, nuanced chromatin language that
recognizes combinations of marks rather than single PTMs
(Berger, 2007).
Simultaneous Binding of Multiple Acetyl-Lysines
to a Single BRD
Recent structural and biophysical studies demonstrated that
murine BRDT requires at least two adjacent acetylation sites
for tight interaction with the histone H4 tails (Morinie`re et al.,
2009). Our SPOT array and ITC data showed that multiple Kac
sites are generally required for specific recognition of the histone
H4 tail by all human BET family members.
We were interested if interactions of diacetyl-lysine also occur
outside the BET BRD family. Using rigid docking of the H4K5ac
K8ac peptide onto all available crystal structures revealed that
a number of other BRDs would have an acetyl-lysine binding
site architecture that would be compatible with the binding of
this diacetylated peptide (data not shown).
The presence of multiple reader modules in chromatin modifi-
cation complexes led to the proposal that distinct epigenetic
signatures are interpreted by a multivalent reading process
that engages diverse binding modules (Ruthenburg et al.,
2007). For instance, recently, the dual-reader module PHD-
BRD in BPTF has been shown to specifically recognize a combi-
nation of H4K16ac and H3K4me3 at the mononucleosome level
(Ruthenburg et al., 2011). Similarly, the tandem Tudor domain
of UHRF1 recognizes H3 when K9 is trimethylated, and K4 is
unmodified, a histone modification state associated with hetero-
chromatin (Nady et al., 2011). Combinations of PHD and BRDs
are particularly frequent and are a hallmark of BRD proteins in
families V and VI, and the PHD-BRD structure showed that the
two reader domains form a single, stable functional unit (Tsai
et al., 2010). The work by Tsai et al. (2010) also suggests that
the TRIM24 PHD-BRD di-domain binds two different histone
tails in opposite orientations. Similarly, our array and ITC studies
on BRD4 showed that the first BRD of this protein has high
affinity for the histone H4 tail, whereas the second BRD most
likely recognizes multiply acetylated marks in histone H3. This
would be consistent with the notion that proteins that harbor
multiple reader domains act as integration platforms for different
chromatin proteins.Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc. 227
Epigenetic Reader Domains Are Promising Drug Targets
BRDs have recently emerged as promising targets for the devel-
opment of protein interaction inhibitors (Chung et al., 2011;
Filippakopoulos et al., 2010; Hewings et al., 2011; Nicodeme
et al., 2010). The acetylation of lysine residues neutralizes
the charge of the primary amine. As a consequence, BRD
acetyl-lysine binding sites are deep and largely hydrophobic
binding pockets that represent attractive targeting sites for the
development of Kac competitive inhibitors. Proteins containing
epigenetic reader modules have been implicated in the develop-
ment of many diseases (Baker et al., 2008; Muller et al., 2011;
Reynoird et al., 2010).
The recent development of potent and highly specific Kac
competitive inhibitors for BET BRDs provides a compelling
case for targeting these BRDs for the treatment of an extremely
aggressive subtype of squamous cell carcinoma that is caused
by chromosomal rearrangement of BRD3 or BRD4 with NUT
(Filippakopoulos et al., 2010; French, 2010b). Recent data
strongly suggested that targeting BET BRDs will be beneficial
for many diverse cancer types due to downregulation of onco-
genes such as c-Myc (Dawson et al., 2011; Delmore et al.,
2011; Mertz et al., 2011). The structural data presented here
provide the foundation for the rational design of selective
BRD inhibitors that will be valuable tools for our understanding
of the role of epigenetic reader modules in health and disease.EXPERIMENTAL PROCEDURES
Protein Purification
BRD constructs were subcloned into pET28-derived expression vectors.
All proteins were expressed as His6-tagged fusions and were purified using
Ni-chelating affinity chromatography. Analytical details for construct design,
protein expression, and purification are given in the Extended Experimental
Procedures and in Tables S1 and S2.
SPOT Assays
Peptides were synthesized on cellulose membranes using a MultiPep SPOT
peptide arrayer (Intavis). His6-tagged BRDs were added to a final concentra-
tion of 1 mM, and blots were developed using an ECL kit (Thermo Scientific)
following the manufacturer’s protocol.
ITC
Experiments were carried out on a VP-ITC or an ITC200 microcalorimeter
(MicroCal, Northampton, MA, USA). In most cases a single binding site model
was employed, supplied with the MicroCal Origin software package.
Crystallization and Structure Determination
Individual proteins were crystallized at either 4C or 20C, and X-ray diffraction
data were collected on beamlines listed in Table S5. Structures were solved
by molecular replacement and were refined as described in detail in the
Extended Experimental Procedures. Crystallization conditions, data collec-
tion, refinement statistics, and PDB accession codes are listed in Tables S3,
S4, and S5.
Histone Immunoprecipitation
HEK293 cells were grown in DMEM with 10% fetal bovine serum (FBS) and
transfected with BRD4-Flag (UniProt: O60885, residues 1–1,362, cloned in
pcDNA5) vector using GeneJuice (EMD) according to the manufacturer’s
instructions. Nucleosome isolation protocol was based on Ruthenburg et al.
(2011) with modification as described in the Extended Experimental
Procedures.228 Cell 149, 214–231, March 30, 2012 ª2012 Elsevier Inc.LC-MS/MS Analysis of Acetylated Histones and Their Quantitation
HeLa cells were grown in DMEM supplemented with 10% FBS and antibiotics
(penicillin-streptomycin). Histones were extracted with high salt (Shechter
et al., 2007) and incubated with recombinant biotinylated BRDs in the pres-
ence of (+)-JQ1 or ()-JQ1 prior to purification on Strep-Tactin Sepharose
beads. After elution of bound histones using trifluoroacetic acid (TFA) and
sample lyophilization, trypsin digestion was performed, and trypsin was
inhibited. Acetylated peptides were purified using anti-Kac agarose beads
(ImmuneChem Pharmaceuticals), and both the unbound fraction and the
bound fraction (eluted in TFA) were prepared for mass spectrometry (MS).
LC-MS/MS was performed using a NanoLC-Ultra 2D plus HPLC system
(Eksigent) coupled to a LTQ-Orbitrap Velos (Thermo Electron) equipped with
a nanoelectrospray ion source (Proxeon Biosystems). Spectra were assigned
by Mascot (Matrix Science, v2.3) against the human RefSeq database
(version 45). Relative quantitation of acetylated peptides was achieved with
Proteome Discoverer 1.2 (Thermo Electron). The efficiency of purification
with each BRD was monitored by analyzing the fraction unbound to anti-Kac;
specificity was ascertained by analyzing the samples incubated with the
inhibitor (+)-JQ1.ACCESSION NUMBERS
The models and structure factors of the reported bromodomain proteins
have been deposited in the Protein Data Bank with the PDB accession
codes 2NXB (BRD3(1)), 2OO1 (BRD3(2)), 2OSS (BRD4(1)), 2OUO (BRD4(2)),
2RFJ (BRDT(1)), 3HME (BRD9), 3D7C (GCN5L2), 3DAI (ATAD2), 3G0L
(BAZ2B), 3GG3 (PCAF), 3DWY (CREBBP), 3UV2 (FALZ), 3IU5 (PB1(1)),
3HMF (PB1(2)), 3K2J (PB1(3)), 3TLP (PB1(4)), 3G0J (PB1(5)), 3IU6 (PB1(6)),
3I3J (EP300), 3HMH (TAF1L(2)), 3UV4 (TAF1(2)), 3LXJ (KIAA1240), 3MQM
(ASH1L), 3MB3 (PHIP(2)), 3UVD (SMARCA4), 3NXB (CECR2), 3Q2E
(WDR9(2)), 3UV5 (TAF1(1/2)), 3RCW (BRD1), 3UVW (BRD4(1)/H4K5acK8ac),
3UVX (BRD4(1)/H4K12acK16ac), 3UVY (BRD4(1)/H4K16acK20ac), 3UW9
(BRD4(1)/H4K8acK12ac), 3P1C (CREBBP/Kac), 3P1D (CREBBP/N-Methyl-2-
pyrrolidone), and 3MB4 (PB1(5)/N-Methyl-2-pyrrolidone).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
supplemental figures, and nine supplemental tables and can be found with this
article online at doi:10.1016/j.cell.2012.02.013.
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